Opening Statement from the January 2021 Intelligent Investor (part 1)
Originally published on January 6, 2021 (pre-market release)
Coronavirus Risks
In late March 2020 I expressed my confidence that a vaccine would be developed before the end of 2020. This view was in stark contrast to all of the “experts” who insisted that a vaccine would not be developed until mid-2021 (best-case) or late 2021 (consensus).
In addition to our recommendations in March 2020 (special webinars and securities research) to overweigh large cap pharma and biopharma stocks, I selected Moderna (MRNA) as the best risk-reward newer small cap biotech as one to consider investing in. Since then, it rose by nearly 600 percent.
I also warned about potential issues with vaccines as well as the likelihood of mutations during the March 2020 coronavirus webinar presentations. Just as I predicted in March 2020, we are now seeing different strains of coronavirus due to mutations.
We do not yet know how effective the vaccines will be against COVID-19. But clearly, the appearance of mutations has already presented a significant risk moving forward.
In March 2020 I also began to discuss the risk of vaccine reluctance from significant numbers of certain populations (especially in the U.S). Although many concerns about the safety of the vaccines are valid, there is a particularly large and growing movement of disinformation from conspiracy nuts and profiteers. If you follow the content on our website you know who some of these individuals are.
This article continues.
To continue viewing this entry please sign in to your Client or Member account.
Restrictions Against Reproduction: No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without the prior written permission of the copyright owner and the Publisher.
These articles and commentaries cannot be reposted or used in any publications for which there is any revenue generated directly or indirectly. These articles cannot be used to enhance the viewer appeal of any website, including any ad revenue on the website, other than those sites for which specific written permission has been granted. Any such violations are unlawful and violators will be prosecuted in accordance with these laws.
Article 19 of the United Nations' Universal Declaration of Human Rights: Everyone has the right to freedom of opinion and expression; this right includes freedom to hold opinions without interference and to seek, receive and impart information and ideas through any media and regardless of frontiers.
This publication (written, audio and video) represents the commentary and/or criticisms from Mike Stathis or other individuals affiliated with Mike Stathis or AVA Investment Analytics (referred to hereafter as the “author”). Therefore, the commentary and/or criticisms only serve as an opinion and therefore should not be taken to be factual representations, regardless of what might be stated in these commentaries/criticisms. There is always a possibility that the author has made one or more unintentional errors, misspoke, misinterpreted information, and/or excluded information which might have altered the commentary and/or criticisms. Hence, you are advised to conduct your own independent investigations so that you can form your own conclusions. We encourage the public to contact us if we have made any errors in statements or assumptions. We also encourage the public to contact us if we have left out relevant information which might alter our conclusions. We cannot promise a response, but we will consider all valid information.